Cargando…
Chronic everolimus treatment of high‐fat diet mice leads to a reduction in obesity but impaired glucose tolerance
Everolimus, which inhibits mTOR kinase activity and is clinically used in graft rejection treatment, may have a two‐sided influence on metabolic syndrome; its role in obesity and hyperglycemic in animals and humans, however, has been explored insufficiently. This study further determined how continu...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955951/ https://www.ncbi.nlm.nih.gov/pubmed/33715287 http://dx.doi.org/10.1002/prp2.732 |